These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 38671379)
1. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study. Ogilvie RP; Layton JB; Lloyd PC; Jiao Y; Djibo DA; Wong HL; Gruber JF; Parambi R; Deng J; Miller M; Song J; Weatherby LB; Peetluk L; Lo AC; Matuska K; Wernecke M; Bui CL; Clarke TC; Cho S; Bell EJ; Yang G; Amend KL; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Anthony MS; Seeger JD; Shoaibi A BMC Pediatr; 2024 Apr; 24(1):276. PubMed ID: 38671379 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States. Layton JB; Peetluk L; Wong HL; Jiao Y; Djibo DA; Bui C; Lloyd PC; Gruber JF; Miller M; Ogilvie RP; Deng J; Parambi R; Song J; Weatherby LB; Lo AC; Matuska K; Wernecke M; Clarke TC; Cho S; Bell EJ; Seeger JD; Yang GW; Illei D; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Amend KL; Anthony MS; Shoaibi A Vaccine X; 2024 Jan; 16():100447. PubMed ID: 38318230 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634 [TBL] [Abstract][Full Text] [Related]
5. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021. Katz MA; Rojas Castro MY; Chakhunashvili G; Chitadze N; Ward CL; McKnight CJ; Lucaccioni H; Finci I; Zardiashvili T; Pebody R; Kissling E; Sanodze L PLoS One; 2024; 19(9):e0307805. PubMed ID: 39240827 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study. Lang AL; Hohmuth N; Višković V; Konigorski S; Scholz S; Balzer F; Remschmidt C; Leistner R J Med Internet Res; 2024 Jun; 26():e47070. PubMed ID: 38833299 [TBL] [Abstract][Full Text] [Related]
11. Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years. Hu M; Shoaibi A; Feng Y; Lloyd PC; Wong HL; Smith ER; Amend KL; Kline A; Beachler DC; Gruber JF; Mitra M; Seeger JD; Harris C; Secora A; Obidi J; Wang J; Song J; McMahill-Walraven CN; Reich C; McEvoy R; Do R; Chillarige Y; Clifford R; Cooper DD; Forshee RA; Anderson SA JAMA Netw Open; 2024 Apr; 7(4):e248192. PubMed ID: 38656578 [TBL] [Abstract][Full Text] [Related]
12. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540 [TBL] [Abstract][Full Text] [Related]
13. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19. Tartof SY; Slezak JM; Frankland TB; Puzniak L; Hong V; Ackerson BK; Stern JA; Zamparo J; Simmons S; Jodar L; McLaughlin JM JAMA Intern Med; 2024 Aug; 184(8):932-940. PubMed ID: 38913355 [TBL] [Abstract][Full Text] [Related]
14. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States. Kirk B; Bush C; Toyip A; Mues KE; Beck E; Li L; St Laurent S; Georgieva M; Marks MA; Sun T; Esposito DB; Martin D; Van de Velde N Vaccine; 2024 Nov; 42(25):126113. PubMed ID: 39030080 [TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
17. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048 [TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
20. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]